Publications by authors named "M J McMorrow"
During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV illness in infants and older adults. CDC, in collaboration with federal, public health, and academic partners, is conducting evaluations of real-world effectiveness of recommended RSV immunization products in the United States. Similar frameworks for evaluation are being applied to RSV vaccines and nirsevimab, a long-acting preventative monoclonal antibody, to estimate product effectiveness.
View Article and Find Full Text PDFImportance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer's maternal RSV vaccine. Postlicensure studies are needed to assess prevention product impact and effectiveness.
Objective: To compare the epidemiology and disease burden of medically attended RSV-associated acute respiratory illness (ARI) among children younger than 5 years during the 2023-2024 RSV season with 3 prepandemic RSV seasons (2017-2020), estimate nirsevimab effectiveness against medically attended RSV-associated ARI, and compare nirsevimab binding site mutations among circulating RSV in infants with and without nirsevimab receipt.
Article Synopsis
- Respiratory syncytial virus (RSV) leads to significant hospitalizations in infants in the US, prompting recommendations for nirsevimab to prevent RSV in all infants under 8 months and at-risk children up to 19 months during their RSV seasons.* -
- A simulation study found that administering nirsevimab could potentially avoid over 107,000 outpatient visits and 14,000 hospitalizations annually if half of newborns receive it, costing approximately $153,517 per quality-adjusted life year (QALY) saved.* -
- The analysis suggests nirsevimab is cost-effective, particularly for high-risk infants, though the cost-per-QALY can vary widely based on factors like hospitalization costs
Background And Objectives: Respiratory syncytial virus (RSV) commonly causes hospitalization among US infants. A maternal vaccine preventing RSV in infants, RSV bivalent prefusion F maternal vaccine (RSVpreF), was approved by the US Food and Drug Administration and recommended by the Advisory Committee on Immunization Practices. Our objective was to evaluate the health benefits and cost-effectiveness of vaccinating pregnant persons in the United States using RSVpreF.
View Article and Find Full Text PDF